Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02000596 · ClinicalTrials.gov registry record · Phase 2
1303GCC: Trastuzmab & Pertuzumab With Hormonal Therapy or Chemotherapy in Women Aged 60 and Over.
A Phase 2 study, sponsored by University of Maryland, Baltimore.
- Terminated
- Registry status
- Phase 2
- Development phase
- 2
- Enrollment target
NCT02000596: Clinical Trial Phase 2 study, sponsored by University of Maryland, Baltimore.
NCT02000596 is a Phase 2 study that was terminated before completion, run by University of Maryland, Baltimore. The registered enrollment target is 2 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02000596, a Phase 2 study, was terminated before completion, sponsored by University of Maryland, Baltimore.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 2 participants
- Enrollment target
Study Summary
This is a phase II study that combines Trastuzumab with Pertuzumab to see how it works in women age greater than 60 who have been diagnosed with HER2/neu overexpressed locally advanced and/or metastatic breast carcinoma.
Primary Outcome
Defined as the total of complete response (CR) defined as a disappearance of all target lesions, partial response (PR) defined as \>= 30% decrease in the sum of the longest diameter of target lesions, and stable disease (SD) \>= 27 weeks among the total number of participants as defined by the Response Evaluation in Solid Tumors (RECIST) 1.1 response criteria.
Interventions
- DRUG Trastuzumab plus Pertuzumab
- DRUG Hormonal Therapy with Anastrozole and Fulvestrant
- DRUG Chemotherapy with Eribulin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2014-01 |
| Est. Completion | 2016-01 |
| Phase | Phase 2 |
Why NCT02000596 stopped before completion
NCT02000596 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 2 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 3 interventions - of which Trastuzumab plus Pertuzumab is the first listed.
NCT02000596 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02000596 about?
NCT02000596 is a clinical study titled "1303GCC: Trastuzmab & Pertuzumab With Hormonal Therapy or Chemotherapy in Women Aged 60 and Over.". This is a phase II study that combines Trastuzumab with Pertuzumab to see how it works in women age greater than 60 who have been diagnosed with HER2/neu overexpressed locally advanced and/or metastatic breast carcinoma.
What is the current status of trial NCT02000596?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 2 participants. The study started on 2014-01. Estimated completion is 2016-01.
What interventions are being tested in trial NCT02000596?
The interventions under investigation include: Trastuzumab plus Pertuzumab (DRUG), Hormonal Therapy with Anastrozole and Fulvestrant (DRUG), Chemotherapy with Eribulin (DRUG).
Who is sponsoring clinical trial NCT02000596?
This trial is sponsored by University of Maryland, Baltimore, which has 560 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02000596's enrollment target sits among peer trials
2 2001st of 2000 the lowest of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia